Canada · Health Care · CAD (Thousands) · Annual
Reported figures and Equlion model projections for the next 4 years.
Amounts in CAD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Crescita Therapeutics Inc.? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | |||
|---|---|---|---|---|---|
| Metric | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -0.59% | -0.15% | -3.63% | -6.67% | -9.57% |
|---|---|---|---|---|---|
| ROA | -0.44% | -0.11% | -2.52% | -4.17% | -5.23% |
| Gross Margin | 45.91% | 51.9% | 51% | 49.74% | 49.2% |
| Net Margin | -0.44% | -0.09% | -2.13% | -3.42% | -4.2% |
| Total Assets | CA$20,328.00K | CA$21,399.32K | CA$22,569.47K | CA$23,847.67K | CA$25,117.79K |
| Net Income | -CA$92.00K | -CA$22.61K | -CA$554.93K | -CA$967.50K | -CA$1,280.93K |